

NON PROPRIETARY**FINAL CRADA REPORT**

Date: 2 October 2009

CRADA Number: 0500801

CRADA Title: Supply of purified Th228 for Ra224 generators

CRADA Start/End Date: 1 January 2007/12 February 2008

Argonne Dollars: \$31,175
Participant Dollars: \$31,175

Argonne PI: David Ehst

Industrial Partner: AlphaMed Inc. (20 Juniper Ridge Rd., Acton, MA 01720)

DOE Program Manager: Regina Carter

Summary of Major Accomplishments: CRADA was terminated when it was determined that the Russians could not perform the terms of the subcontract.

Summary of Technology Transfer Benefits to Industry: It became apparent that the Russians would not be a reliable source of Th228, as a precursor in the decay chain which leads to Ra224. Their government policies will prohibit the export of Th228 in quantities needed for commercial cancer therapy.

Other Information/Results: (Papers, Inventions, Software, etc.)

AMI email to Nerozin.12feb08 [Word document, correspondence explaining reasons for terminating the relationship.]